Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Freenome, Inc. (FRNM)

Freenome: FDA approves SimpleScreen CRC blood test; Abbott to commercialize in U.S.

Positive Impact 4 of 5 product/contract Written later

The FDA approved Freenome's SimpleScreen CRC, a blood-based colorectal cancer screening test for adults 45 and older at average risk. Under an August 2025 agreement, Freenome will receive a $100 million milestone payment from Abbott, which will exclusively commercialize the test in the U.S. this fall.

Key points

  • FDA approved SimpleScreen CRC for adults 45 and older at average risk for colorectal cancer, announced July 27, 2026.
  • In the PREEMPT CRC study of more than 48,000 adults, the test showed 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia.
  • Freenome will receive a $100 million milestone payment from Abbott for the FDA approval; Abbott plans to commercialize the test in the U.S. this fall.

The filing

CompanyFreenome, Inc. (FRNM)
Form8-K, current report
Filed with the SECJul 27, 2026, 8:10 AM ET
Accession number0001140361-26-029689

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.